Discovery Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Discovery Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-548,727	Closed	-$499K	–	70
2023 Q1	$499K	Hold	548,727	–	–	0.06%	54
2022 Q4	$466K	Buy	+548,727	New	+$486K	0.07%	48

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Discovery Capital Management's CRVS Position: Q2 2023 in Review

Discovery Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2023, closing a stake of 548,727 shares — an estimated $499K sold.

Discovery Capital Management first reported a position in CRVS in Q4 2022 and held it in 2 quarters. The position peaked at $499K in Q1 2023. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2023.

Discovery Capital Management reported no remaining Corvus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Discovery Capital Management sold 548,727 Corvus Pharmaceuticals shares in Q2 2023, an estimated $499K.
Discovery Capital Management first reported a position in Corvus Pharmaceuticals in Q4 2022 and held it in 2 quarters.
Discovery Capital Management's Corvus Pharmaceuticals position peaked at $499K in Q1 2023.
52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2023.

Based on Discovery Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.